Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a …

T Craig, M Magerl, DS Levy, A Reshef, WR Lumry… - The Lancet, 2022 - thelancet.com
Background Hereditary angioedema is associated with dysregulation of the kallikrein–kinin
system. Factor XII (FXII) is a key initiator of the kallikrein–kinin system, which produces …

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind …

TJ Craig, A Reshef, HH Li, JS Jacobs, JA Bernstein… - The Lancet, 2023 - thelancet.com
Background Hereditary angioedema is a rare and potentially life-threatening genetic
disease that is associated with kallikrein–kinin system dysregulation. Garadacimab …

Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled …

MA Riedl, V Grivcheva-Panovska, D Moldovan, J Baker… - The Lancet, 2017 - thelancet.com
Background Hereditary angio-oedema is a recurrent, oedematous disorder caused by
deficiency of functional C1 inhibitor. Infusions of plasma-derived C1 esterase inhibitor deter …

Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial

MA Riedl, JA Bernstein, H Li, A Reshef, W Lumry… - Annals of Allergy …, 2014 - Elsevier
Background Hereditary angioedema (HAE), caused by C1 inhibitor (C1INH) deficiency or
dysfunction, is characterized by recurrent attacks of tissue swelling affecting multiple …

Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor

H Longhurst, M Cicardi, T Craig, K Bork… - New England journal …, 2017 - Mass Medical Soc
Background Hereditary angioedema is a disabling, potentially fatal condition caused by
deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use …

C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks–final results of the IMPACT 2 study

TJ Craig, AK Bewtra, SL Bahna, D Hurewitz… - Allergy, 2011 - Wiley Online Library
To cite this article: Craig TJ, Bewtra AK, Bahna SL, Hurewitz D, Schneider LC, Levy RJ, Moy
JN, Offenberger J, Jacobson KW, Yang WH, Eidelman F, Janss G, Packer FR, Rojavin MA …

Inhibiting plasma kallikrein for hereditary angioedema prophylaxis

A Banerji, P Busse, M Shennak, W Lumry… - New England journal …, 2017 - Mass Medical Soc
Background Hereditary angioedema with C1 inhibitor deficiency is characterized by
recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein …

[HTML][HTML] Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema

E Aygören-Pürsün, A Bygum… - … England Journal of …, 2018 - Mass Medical Soc
Background Hereditary angioedema is a life-threatening illness caused by mutations in the
gene encoding C1 inhibitor (also called C1 esterase inhibitor) that lead to overactivation of …

Treatment of Hereditary Angioedema.

T Caballero - Journal of Investigational Allergology & Clinical …, 2021 - europepmc.org
Hereditary angioedema due to C1-esterase inhibitor deficiency (C1-INH-HAE) is a rare
autosomal dominant disease. In the last decade, new drugs and new indications for old …

[HTML][HTML] Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks

HH Li, D Moldovan, JA Bernstein, A Reshef… - The Journal of Allergy …, 2015 - Elsevier
Background Hereditary angioedema (HAE) caused by a deficiency in functional C1 esterase
inhibitor (C1INH) is characterized by recurrent episodes of cutaneous and/or …